Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus ZORVOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus ZORVOLEX.
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE vs ZORVOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Diphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms and inducing sedation via central H1 blockade.
ZORVOLEX (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
One tablet (naproxen sodium 220 mg / diphenhydramine hydrochloride 25 mg) orally every 8 hours as needed, not to exceed 2 tablets in 24 hours.
50 mg orally every 8 hours or 100 mg orally every 12 hours; maximum 200 mg/day.
None Documented
None Documented
Naproxen: 12-17 hours (mean ~14 hours); clinically, allows twice-daily dosing for sustained anti-inflammatory effect. Diphenhydramine: 4-10 hours (mean ~7 hours); shorter half-life supports sedative effect for sleep induction.
Terminal elimination half-life of the dual-release formulation is approximately 6-7 hours. Clinical context: Allows twice-daily dosing for sustained analgesic effect.
Naproxen: renal excretion of naproxen and its metabolites (95% as unchanged drug and conjugated metabolites, primarily 6-O-desmethylnaproxen). Diphenhydramine: renal excretion of unchanged drug and metabolites (primarily as diphenylmethoxyacetic acid); approximately 50-60% eliminated in urine as unchanged drug and metabolites, with a small fraction in feces.
Renal excretion of metabolites and conjugates accounts for approximately 50% of the dose, with biliary/fecal elimination of the remainder. Less than 5% is excreted unchanged in urine.
Category D/X
Category C
NSAID
NSAID